In 2022, the FDA approved the rabbit monoclonal primary antibody VENTANA PATHWAY anti-HER2/neu (4B5) as the sole diagnostic test to identify patients with metastatic breast cancer with low HER2 expression for whom T-Dxd may be considered as a specific targeted treatment [24,25]. Here, ERBB2 is linked to breast cancer.